Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia

Course Information

Therapautic Area: Cardiology
Format(s): Webcast
Credit(s): 1.50 AMA PRA Category 1 Credit(s)™
Activity Dates: December 19, 2017 to December 18, 2018


Program Overview

The content for this activity is derived from a live symposium titled, “Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will highlight optimal treatment and management strategies for patients with dyslipidemia in the era of PCSK9 inhibitors. The expert faculty will review recent clinical trial and CVD outcomes data, encompassing lipid lowering therapies for the diabetic patient subset. Dyslipidemia guidelines as well as strategies for achieving LDL-C goal will be outlined, particularly in the high-risk population. Dr. Christopher P. Cannon and the accompanying faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision- making. This CME program will provide cardiologists with vital information for improving healthcare outcomes in patients with dyslipidemia.

Target Audience

Cardiologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Identify the current dyslipidemia guidelines and consensus statements to achieve LDL-C goal
  2. Compare available pharmacotherapies that reduce LDL-C
  3. Analyze the details of the CVD outcomes trial data for patients on PCSK9 inhibitors, including the diabetic patient subset
  4. Prioritize the most current treatment plans for patients with familial hypercholesterolemia
  5. Apply current algorithms and treatment models for managing the high-risk patient with dyslipidemia


Cannon HeadshotChristopher P. Cannon, MD (Chair)
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts


Ballantyne HeadshotChristie M. Ballantyne, MD
Professor of Medicine
Vice-Chair of Research-Department of Medicine
Chief-Section of Cardiology
Chief-Section of Cardiovascular Research
Baylor College of Medicine
Houston, Texas


Brown HeadshotAlan S. Brown, MD
Director, Division of Cardiolog
Advocate Lutheran General Hospital
President-Elect, National Lipid Association
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch Medical School
Park Ridge, Illinois


Eckel Headshot #4Robert H. Eckel, MD
Professor of Medicine
Division of Endocrinology, Metabolism, and Diabetes, and Cardiology
Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado
Anschutz Medical Campus
Aurora, Colorado


Giugliano HeadshotRobert P. Giugliano, MD, SM
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts


Underberg #6James A. Underberg, MD, MS
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, New York




Provided by AcademicCME.

Screen Shot 2016-02-03 at 2.55.09 PM